Skip to main content Skip to section navigation Skip to footer

Vyant Bio, Inc.

  • Investors
  • Overview
  • News & Events
    • Overview
    • Press Releases
    • In the News
    • IR Calendar
    • Email Alerts
  • Company Info
    • Overview
    • Management Team
    • Contacts
    • FAQ
  • Documents
    • Presentations
    • Scientific Documents
    • Videos
  • Financial Info
    • Overview
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
  • Stock Data
    • Quote
    • Charts
    • Historical Data
    • Analyst Coverage
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
    • Board Diversity Matrix

In the News

News & Events

News & Events

  • Overview
  • Press Releases
  • In the News
  • IR Calendar
  • Email Alerts
May 16, 2022

Proactive Investors: Vyant Bio Ends 1Q with $16.4M in Cash to Fund Small Molecule Therapeutics Research for Neurological Diseases

Apr 1, 2022

Parkinson’s News Today: Vyant Bio, OrganoTherapeutics Will Use Organoids for New Therapies

Mar 30, 2022

Proactive Investors: Vyant Bio Ends 2021 with $20.6M in Cash as It Sharpens Focus on Novel Drug Discovery

Mar 29, 2022

Proactive Investors: Vyant Bio Enters Collaboration with OrganoTherapeutics to Find Treatments for Parkinson's Disease

Mar 10, 2022

Proactive Investors: Vyant Bio Fires Up Its Drug Discovery Engine to Speed Up Novel Therapeutics for Brain Diseases

Mar 1, 2022

Proactive Investors: Vyant Bio Says It is ‘Well-Positioned’ to Discover Novel Therapeutics to Treat Neurological Diseases

Dec 1, 2021

Nature: Transforming Drug Discovery to Get More Breakthrough Medicines to Patients

Nov 15, 2021

Pharma Tech Outlook: Vyant Bio [NASDAQ: VYNT]: Human-First Approach to Drug Discovery

Nov 11, 2021

Proactive Investors: Vyant Bio Reports Total Revenue of $1.5M in 3Q 2021, Shares Strategic Updates

Oct 26, 2021

Proactive Investors: Vyant Bio Appoints Robert Fremeau as Chief Scientific Officer

RSS
  • 1
  • 2
  • Next
  • Email Alerts
  • Contacts
  • RSS News Feed

Contact Us

Global locations in the US, Europe, and Australia.

Twitter LinedIn
©2023 Vyant Bio, Inc. All Rights Reserved.